Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
  • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
  • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
  • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/18—Feminine contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
  • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C2601/00—Systems containing only non-condensed rings
  • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring

Definitions

• the present invention relates to novel naphthalenic derivatives, process for their preparation and pharmaceutical compositions containing them.
• the compounds of the present invention are novel and have very interesting pharmacological characteristics concerning melatoninergic receptors.
• melatonin N-acetyl-5-methoxytryptamine
• melatonin analogues which are metabolically more stable and have an agonist or antagonist character, which can be expected to have a therapeutic effect greater than that of the hormone itself.
• the melatoninergic system ligands possess interesting pharmacological properties on the central nervous system, including anxiolytics and antipsychotics
• the compounds of the present invention in addition to their novelty, show a very high affinity for melatonin receptors.
• the present invention relates more particularly to the compounds of formula (I):
• R 1 represents an alkyl group (C 1 -C 6) linear or branched, alkenyl (C 1 -C 6) linear or branched haloalkyl (Ci-C 6) linear or branched polyhaloalkyl (Ci-C 6) linear or branched , cycloalkyl (C 3 -C 8) cycloalkyl (C 3 -C 8) alkyl (C 1 -C 6) whose alkyl moiety may be linear or branched, aryl, aryl (Ci-C 6) whose alkyl moiety may be linear or branched, heteroaryl or heteroarylalkyl (C 1 -C 6 ) whose alkyl part may be linear or branched
• R 2 represents a fluorine atom or a linear or branched (C 1 -C 6 ) alkyl group substituted with one or more fluorine atoms
• aryl means a phenyl, naphthyl or biphenyl group
• heteroaryl means any mono or bicyclic aromatic group containing
• 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen may be substituted by 1 to 3 groups selected from alkyl (C 1 -C 6) linear or branched alkoxy (C 1 -C 6) linear or branched, hydroxy, carboxy, formyl, nitro, cyano, halo (C 1 -C 6) linear or branched polyhaloalkyl (C 1 -C 6) linear or branched alkyloxycarbonyl, or halogen atoms,
• hydrochloric hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic and methane acids. sulfonic, camphoric, etc.
• pharmaceutically acceptable bases mention may be made, without limitation, of sodium hydroxide, potassium hydroxide, triethylamine, tertbutylamine, and the like.
• the preferred compounds of the invention are the compounds of formula (I) for which R 1 represents a linear or branched (C 1 -C 6 ) alkyl group such as, for example, methyl or ethyl groups; or a cycloalkyl (C 3 -C 8 ) group such as, for example, cyclopropyl and cyclobutyl groups; or a polyhaloalkyl group such as, for example, the fluoromethyl group.
• the group R 2 represents a fluorine atom or a fluoromethyl group or a 1-fluoroethyl group.
• the invention relates to the compounds which are N- [2-fluoro-2- (7-methoxy-1-naphthyl) ethyl] acetamide, N- [2-fluoro-2- (7-methoxy) 1-Naphthyl) ethyl] propanamide, N- [2-fluoro-2- (7-methoxy-1-naphthyl) ethyl] cyclopropanecarboxamide, J / V- [2-fluoro-2- (7-methoxy) -1- naphthyl) ethyl] cyclobutanecarboxamide, 7V- [3-fluoro-2- (7-methoxy-1-naphthyl) propyl] acetamide, 2-fluoro-N- [3-fluoro-2- (7-methoxy) -1- naphthyl) propyl] acetamide, and N- [4-fluoro-2- (7-methoxy
• the invention also extends to the process for the preparation of the compound of formula (I), characterized in that the compound of formula (II) used is the starting material:
• R 2 is as defined in formula (I), which is subjected to the action of the compound of formula R] COCl wherein R 1 is as defined in formula (I) to yield the compound of formula (I) which can be purified according to a conventional separation technique, which is converted, if desired, into its addition salts with a pharmaceutically acceptable acid or base and the isomers are optionally separated therefrom in accordance with classical separation technique.
• An advantageous variant relates to the process for the preparation of the compounds of formula (I) for which R 2 represents a linear or branched (C 1 -C 6 ) alkyl group substituted with one or more fluorine atoms, characterized in that one uses as a starting product compound of formula (III):
• R 1 is as defined in formula (I) and R represents a linear or branched (C 1 -C 6 ) alkyl group substituted by one or more OH groups, which is subjected to the action of methane chloride sulfonyl to yield the compound of formula (IV):
• R 1 is as defined in formula (I) and R 'represents a linear or branched (C 1 -C 6 ) alkyl group substituted by one or more 2 Me OSO groups, which is subjected to the action of tetrabutylammonium fluoride to yield the compound of formula (Va), in particular the compounds of formula (I):
• R ' 2 represents a linear or branched (Cj-C 6 ) alkyl group substituted with one or more fluorine atoms
• compounds of formula (I / a) which can be purified according to a conventional separation technique, which is If desired, it converts into their addition salts with a pharmaceutically acceptable acid or base and the isomers are optionally separated therefrom by a conventional separation technique.
• the compounds of formula (II) and (III) are either commercially available or accessible to those skilled in the art by conventional chemical reactions and described in the literature.
• the pharmacological study of the derivatives of the invention has shown that they are atoxic, endowed with a high selective affinity for melatonin receptors and have important activities on the central nervous system and, in particular, have been noted.
• therapeutic properties on sleep disorders, antidepressant, anxiolytic, antipsychotic, analgesic and microcirculation properties which make it possible to establish that the products of the invention are useful in the treatment of stress, sleep disorders, anxiety, seasonal depression or major depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, schizophrenia, panic attacks, melancholy, disorders of the appetite, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders related to normal or pathological aging, migraine, memory loss, Alzheimer's disease, as well as disorders of the cerebral circulation.
• the products of the invention can be used in sexual dysfunctions, that they have properties of ovulation inhibitors, immunomodulators and that they are
• the compounds will preferably be used in the treatment of major depression, seasonal depression, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, appetite disorders and obesity.
• the compounds will be used in the treatment of major depression, seasonal depression and sleep disorders.
• the present invention also relates to pharmaceutical compositions containing at least one compound of formula (I) alone or in combination with one or more pharmaceutically acceptable excipients.
• pharmaceutical compositions according to the invention mention may be made, more particularly, of those which are suitable for oral, parenteral, nasal, percutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets. , sachets, packets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and oral or injectable ampoules.
• the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.01 mg and 1 g per 24 hours. in one or more takes.
• Step A 2- (7-Methoxy-1-naphthyl) ethyl methanesulfonate
• Stage B 7-Methoxy-1-vinylnaphthalene
• the compound obtained in Step A (21.4 mmol) is dissolved in 120 ml of tetrahydrofuran and potassium t-butoxide (64.2 mmol) is added in small portions. After stirring for 30 minutes at room temperature, the reaction medium is evaporated to dryness. The residue obtained is taken up in 150 ml of water and the aqueous phase is extracted with twice 60 ml of diethyl ether. The organic phase is washed with water, dried over magnesium sulfate, decolorized on vegetable charcoal and evaporated. The residue obtained is purified on silica gel (eluent: petroleum ether) to yield the title product in the form of a yellow oil.
• the compound obtained in Stage B (5.4 mmol) is solubilized in 25 ml of dichloromethane, and this solution is then cooled to 0 ° C. using an ice bath. Triethylamine trihydrogen fluoride (16.3 mmol) and N-bromosuccinimide (6.5 mmol) are added. The reaction medium is stirred for 30 minutes at 0 ° C. and 12 hours at room temperature. The reaction medium is poured into ice water, neutralized with a 28% ammonia solution and extracted with dichloromethane. The organic phase is washed with 0.1 M hydrochloric acid solution, with 5% sodium hydrogencarbonate solution and with water. The organic phase is dried over magnesium sulphate and the solvent is evaporated under reduced pressure. The residue obtained is purified by chromatography on silica gel (eluent: petroleum ether / dichloromethane 9/1) to yield the title product in the form of a brown oil.
• Triethylamine trihydrogen fluoride (16.3
• the sodium azide (15.3 mmol) is suspended in 10 ml of dimethylformamide, tetrabutylammonium bromide (200 mg) is added and the medium is heated at 70 ° C for 30 minutes.
• the compound obtained in Stage C is then added in solution in 20 ml of dimethylformamide and the medium is stirred at 70 ° C. for 2 hours.
• 40 ml of water are added and the aqueous phase is extracted with 3 times 60 ml of ether.
• the organic phase is then washed with an acid solution hydrochloric acid 2M then with water, dried and evaporated under reduced pressure to yield the title product in the form of a yellow oil.
• the aluminum chloride (80 mmol), solubilized in 200 ml of anhydrous ether, is added to a suspension of lithium aluminum hydride (80 mmol) at 0 ° C. in 300 ml of anhydrous ether.
• the compound obtained in Stage D (20 mmol) dissolved in 200 ml of anhydrous ether is added.
• the medium is cold hydrolyzed and carefully with a sodium hydroxide solution (250 mmol).
• the formed mineral precipitate is then filtered and extensively washed with ether.
• the residue obtained after evaporation is taken up in water and the aqueous phase is extracted with dichloromethane.
• the organic phase is then washed with water, dried, decolorized, then treated with gaseous hydrochloric acid and evaporated.
• the oil obtained precipitates in ethyl acetate and the precipitate formed is filtered off and then recrystallized.
• Step E The compound obtained in Step E (20 mmol) is dissolved in a water / ethyl acetate mixture (25 ml / 75 ml) cooled to 0 ° C. Potassium carbonate (60 mmol) is added and the acetyl chloride (26 mmol) is added dropwise to the reaction medium. The whole is stirred vigorously for 30 minutes at room temperature. The two phases are separated and the organic phase is washed with an aqueous solution of 0.1 M hydrochloric acid and then with water. After drying over magnesium sulphate, the organic phase is evaporated under reduced pressure. The residue obtained is recrystallized from a toluene / cyclohexane mixture (5/5) to give the title product in the form of a white solid.
• Step A 3-Amino-2- (7-methoxy-1-naphthyl) -1-propanol, hydrochloride
• Step B The compound obtained in Step B (10.9 mmol) is solubilized in 160 ml of dichloromethane, triethylamine (16.8 mmol) is added and the solution is cooled to 0 ° C. with an ice bath.
• the methanesulfonyl chloride (16.8 mmol) is then added dropwise and the mixture is stirred at room temperature for 15 minutes.
• the mixture is poured into water and the organic phase is washed with a 0.5N hydrochloric acid solution and then with a solution of 5% sodium hydrogen carbonate and with water.
• the organic phase is then dried and evaporated cold.
• the oil obtained after evaporation precipitates in ether.
• the precipitate obtained is filtered off but not recrystallized and gives the title product in the form of a white solid. Melting point: 104-106 ° C.
• the reaction medium is poured into water and extracted with twice 50 ml of diethyl ether.
• the organic phase is dried over magnesium sulfate.
• the oil obtained after evaporation of the solvent is purified on silica gel (eluent: acetone / cyclohexane 4/6) to yield, after recrystallization from cyclohexane, the title product in the form of a white solid. Melting point: 87-89 ° C
• Example 6 2-Fluoro-N- [3-fluoro-2- (7-methoxy-1-naphthyl) propyl] acetamide
• Step A 3-Amino-2- (7-methoxy-1-naphthyl) -1-propanol , hydrochloride
• the aluminum chloride (80 mmol) solubilized in 200 ml of anhydrous ether, is added to a suspension of lithium aluminum hydride (80 mmol) at 0 ° C. in 300 ml of anhydrous ether.
• Step B 2-fluoro-7- [3-hydroxy-2- (7-methoxy-1-naphthyl) propyl] acetamide
• Step A The compound obtained in Step A (20 mmol) is dissolved in a water / ethyl acetate mixture (25 ml / 75 ml) cooled to 0 ° C. Potassium carbonate (60 mmol) is added and then the fluoroacetyl chloride (26 mmol) is added dropwise to the reaction medium.
• the two phases are separated and the organic phase is washed with an aqueous solution of 0.1 M hydrochloric acid and then with water. After drying over magnesium sulphate, the organic phase is evaporated under reduced pressure. The resulting residue is recrystallized from diisopropyl ether to yield the title product as a white solid.
• Step B The compound obtained in Step B (10.9 mmol) is solubilized in 160 ml of dichloromethane, triethylamine (16.8 mmol) is added and the solution is cooled to 0 ° C. with an ice bath. Methanesulfonyl chloride (16.8 mmol) is then added dropwise and the medium is stirred at room temperature for 15 minutes. At the end of the reaction, the mixture is poured into water and the organic phase is washed with a 0.5N hydrochloric acid solution and then with a solution of 5% sodium hydrogen carbonate and with water. The organic phase is then dried and evaporated cold. The oil obtained after evaporation precipitates in ether. The precipitate obtained is filtered off but not recrystallized and gives the title product in the form of a white solid. Melting point: 122-124 ° C
• reaction medium is poured into water and extracted with twice 50 ml of diethyl ether.
• organic phase is dried over magnesium sulfate.
• the oil obtained after evaporation of the solvent is purified on silica gel (eluent: acetone / cyclohexane 4/6) to yield, after recrystallization in diisopropyl ether, the title product in the form of a white solid.
• the compound is obtained from methyl 2-cyano-2- (7-methoxy-1-naphthyl) propanoate according to the process described in Steps A to D of Example 5. Melting point: 81-82 ° C PHARMACOLOGICAL STUDY
• Acute toxicity was assessed after oral administration to batches of 8 mice (26 ⁇ 2 grams). The animals were observed at regular intervals during the first day and daily for two weeks after treatment. The LD 50, resulting in the death of 50% of the animals, was evaluated and showed the low toxicity of the compounds of the invention.
• the compounds of the invention are tested in a behavioral model, the forced swimming test.
• the apparatus consists of a Plexiglas cylinder filled with water.
• the animals are tested individually during a 6-minute session. At the beginning of each test, the animal is placed in the center of the cylinder. The downtime is recorded. Each animal is judged immobile when it ceases to struggle, and remains on the surface of the water, motionless, making only the movements allowing it to keep its head out of the water.
• the compounds of the invention significantly reduce the duration of immobilization attesting to their antidepressant activity.
• MTi or MT 2 receptor binding experiments were performed using 2- [ 125 I] -iodomelatonin as a reference radioligand. The retained radioactivity is determined using a liquid scintillation counter.
• the Kj values found for the compounds of the invention attest to a binding for one or other of the melatoninergic binding sites, these values being ⁇ 10 ⁇ M.
• the compound obtained in Example 5 has a Kj (MT 1 ) of 0.1 nM, and
• the affinity of the compounds for human 5-HT receptor 2 c is evaluated on membrane preparations from CHO cells stably expressing that receptor.
• the incubation is carried out in 50 mM TRIS buffer, pH 7.4 containing 10 mM MgCl 2 and 0.1% BSA, in the presence of [ 3 H] mesulergine (1 nM) and 25 fmol / ml of receiver. Nonspecific binding is determined in the presence of 10 ⁇ M mianserin.
• the reaction is stopped by the addition of 50 mM TRIS buffer, pH 7.4 followed by a filtration step and 3 successive rinses: the radioactivity bound to the membranes remaining on the filters (GF / B pretreated with 0.1% PEI) is counted as liquid scintillation.
• the compounds of the invention are affine for the 5-HT 2C receptor with Kj ⁇ 10 ⁇ M.
• the compound of Example 5 has a Ki (5-HT 2C) of 6 .mu.M.
• One-month-old male rats are subjected to a light cycle of 12 hours of light per day as soon as they arrive at the laboratory (LD 12:12). After 2 to 3 weeks of adaptation, they are placed in cages equipped with a wheel connected to a recording system in order to detect the phases of locomotor activity and thus to follow the diurnal (LD) or circadian (DD) rhythms. ).
• LD 12 12
• the rats are put in permanent darkness (DD). Two to three weeks later, when the free-course (rhythm reflecting that of the endogenous clock) is clearly established, the rats receive a daily administration of the molecule to be tested.
• the compounds of the invention are tested in a behavioral model, the light / dark cages test, which reveals the anxiolytic activity of the molecules.
• the device consists of two polyvinyl boxes covered with Plexiglas. One of these boxes is obscure. One lamp is placed above the other box giving a luminous intensity in the center of it of approximately 4000 lux. An opaque plastic tunnel separates the clear box from the dark box. The animals are tested individually during a 5 min session. The floor of each box is cleaned between each session. At the beginning of each test, the mouse is placed in the tunnel, facing the dark box. The time spent by the mouse in the lighted box and the number of transitions through the tunnel are recorded after the first entry in the dark box. After administration of the compounds 30 min before the start of the test, the compounds of the invention significantly increase the time spent in the illuminated cage and the number of transitions, which shows the anxiolytic activity of the derivatives of the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Endocrinology (AREA)
• Diabetes (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Immunology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Cardiology (AREA)
• Anesthesiology (AREA)
• Psychology (AREA)
• Child & Adolescent Psychology (AREA)
• Hospice & Palliative Care (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Epidemiology (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=38926225

Family Applications (1)

Country Status (16)

Families Citing this family (3)

Family Cites Families (6)

• 2007
  • 2007-07-02 FR FR0704748A patent/FR2918370B1/fr not_active Expired - Fee Related
• 2008
  • 2008-07-01 EA EA201000084A patent/EA201000084A1/ru unknown
  • 2008-07-01 JP JP2010514038A patent/JP2010531860A/ja active Pending
  • 2008-07-01 AU AU2008288374A patent/AU2008288374B2/en not_active Ceased
  • 2008-07-01 CN CN200880022964A patent/CN101687772A/zh active Pending
  • 2008-07-01 CA CA002691593A patent/CA2691593A1/fr not_active Abandoned
  • 2008-07-01 WO PCT/FR2008/000933 patent/WO2009022064A2/fr not_active Ceased
  • 2008-07-01 BR BRPI0814407A patent/BRPI0814407A2/pt not_active IP Right Cessation
  • 2008-07-01 EP EP08827416A patent/EP2167457A2/fr not_active Withdrawn
  • 2008-07-01 MX MX2010000001A patent/MX2010000001A/es unknown
  • 2008-07-01 UA UAA201000634A patent/UA94827C2/ru unknown
  • 2008-07-01 KR KR1020107002340A patent/KR20100029263A/ko not_active Ceased
  • 2008-07-01 US US12/452,456 patent/US20100137446A1/en not_active Abandoned
  • 2008-07-02 AR ARP080102857A patent/AR070006A1/es unknown
• 2010
  • 2010-01-04 ZA ZA2010/00025A patent/ZA201000025B/en unknown
  • 2010-02-01 MA MA32572A patent/MA31578B1/fr unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events